Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

One of Europe’s leading VCs banks a €725M ‘crossover’ fund

BioPharma DiveView source article

Part of story

Sofinnova Partners raises €725M crossover fund for late-stage European biotechs

Paris-based Sofinnova Partners secured €725 million ($815 million) for its second crossover fund targeting late-stage European biopharma companies, addressing a financing gap in the sector.

Nov 16, 2026·3 sourcesBiotech innovationBiotechnologyPharmaceutical IndustryVenture capital funding
Sofinnova Partners raises €725M crossover fund for late-stage European biotechs
00

Other sources for this story

Axios

Sofinnova Partners raises €725M fund to back late-stage biotechs

Endpoints

Sofinnova amasses €725M for late-stage European biotechs